Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04338685 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases
A Phase 1 study of Biliary Tract Cancer and Liver Metastases, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
- 10
- Study locations
NCT04338685: Completed Phase 1 study of Biliary Tract Cancer and Liver Metastases, sponsored by Hoffmann-La Roche.
NCT04338685 is a Phase 1 study of Biliary Tract Cancer and Liver Metastases that has completed, run by Hoffmann-La Roche. The registered enrollment target is 55 participants, below the 238-participant average among 36 other Biliary Tract Cancer trials with a reported enrollment target (77% lower). The trial reports 10 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04338685, a Phase 1 study of Biliary Tract Cancer and Liver Metastases, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
- 10
- Study locations
Study Summary
Phase I study of RO7119929 given orally to participants with unresectable advanced or metastatic primary liver cancers and other solid tumors with predominant liver involvement. The primary objective of the study is to explore the safety and to determine the maximum tolerated dose (MTD) and/or optimal biologic dose (OBD) of RO7119929 as single agent.
Primary Outcome
A DLT is defined as a clinically significant AE (classified according to the National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE\] v.5.0) or significant laboratory abnormality 1) occurring during an assessment period of 21 days or 28 days after first dose of study treatment, respectively, and 2) is not attributed to disease progression, concomitant illness or another clearly identifiable cause.
Conditions Studied
Interventions
- DRUG Tocilizumab
- DRUG RO7119929
Study Locations (10)
Other
- Rigshospitalet; Onkologisk Klinik - København Ø
- Queen Mary Hospital; Dept of Medicine - Hong Kong
- Seoul National University Hospital - Seoul
- Asan Medical Center - Seoul
- Hospital Universitari Vall d'Hebron; Oncology - Barcelona
- Clinica Universidad de Navarra Madrid; Servicio de Oncología - Madrid
- National Taiwan Uni Hospital - Taipei
- Tri-Service General Hospital - Taipei
California
- City of Hope Cancer Center - Duarte
Navarre
- Clínica Universidad de Navarra - Pamplona
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2020-07-16 |
| Est. Completion | 2023-01-09 |
| Phase | Phase 1 |
What the finished NCT04338685 record still lists
NCT04338685 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 238-participant average among 36 other Biliary Tract Cancer trials with a reported enrollment target (77% lower).
The record links to 4 conditions, with Biliary Tract Cancer appearing as the primary indexed condition, and to 2 interventions - of which Tocilizumab is the first listed.
NCT04338685 lists 10 locations in 3 states (Other, California, Navarre).
Frequently Asked Questions
What is clinical trial NCT04338685 about?
NCT04338685 is a clinical study titled "A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases". Phase I study of RO7119929 given orally to participants with unresectable advanced or metastatic primary liver cancers and other solid tumors with predominant liver involvement. The primary objective of the study is to explore the safety and to determine the maximum tolerated dose (MTD) and/or optim...
What is the current status of trial NCT04338685?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2020-07-16. Estimated completion is 2023-01-09.
What conditions does trial NCT04338685 study?
This clinical trial studies the following conditions: Biliary Tract Cancer, Liver Metastases, Carcinoma, Hepatocellular, Secondary Liver Cancer.
What interventions are being tested in trial NCT04338685?
The interventions under investigation include: Tocilizumab (DRUG), RO7119929 (DRUG).
Who is sponsoring clinical trial NCT04338685?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04338685 being conducted?
This trial has 10 study locations across California, Navarre. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Biliary Tract Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04338685's enrollment target sits among peer trials
55 27th of 36 higher than 10 of 36 other Biliary Tract Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Biliary Tract Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RECRUITING · Phase 1
-
Study for AZD4360 in Participants With Advanced Solid Tumours
RECRUITING · Phase 1
-
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI